Our Researchers

Research Flagships

Professor Anthony CHAN

Professor Anthony CHAN

Department of Clinical Oncology

Professor CHAN conducted pivotal studies setting the new treatment standard in multimodality approaches in nasopharynx cancer, developed the clinical application of the biomarker EBV DNA and pioneered immunotherapeutic and targeted therapeutics in this disease.

Flagship: Asian Prevalent Cancers

Professor Rossa CHIU

Professor Rossa CHIU

Department of Chemical Pathology

Professor CHIU has made significant contributions to the development of non-invasive prenatal diagnosis. Recently, she has been investigating the detection of cancer-derived DNA in human plasma with an aim to develop non-invasive blood tests for cancer detection.

Flagship: Circulating Fetal Nucleic Acids

Professor Kwok Wai LO

Professor Kwok Wai LO

Department of Anatomical and Cellular Pathology

Professor LO has successfully delineated the early events in NPC tumourigenesis and determined multiple recurrent genetic and epigenetic abnormalities in this EBV-associated cancer. Recently, he has systematically characterised the NPC genome by next-generation sequencing approaches.

Flagship: Asian Prevalent Cancers

Professor Dennis LO

Professor Dennis LO

Department of Chemical Pathology

Professor LO discovered the presence of cell-free fetal DNA in maternal plasma in 1997 and has since then been pioneering non-invasive prenatal diagnosis using this technology.

Flagship: Circulating Fetal Nucleic Acids

Professor Ronald MA

Professor Ronald MA

Department of Medicine and Therapeutics

Professor MA’s research group was the first to identify a genetic variant near the PAX4 gene as a novel predictor of type 2 diabetes in Chinese and other Asian populations. He is currently leading a multidisciplinary project team to identify novel molecular markers for diabetic complications, funded by the Theme-based research scheme.

Flagship: Diabetes

Professor Ka Fai TO

Professor Ka Fai TO

Department of Anatomical and Cellular Pathology

Professor TO’s research team reported the genomic landscape of the largest cohort of micro-dissected EBV-positive NPC as published to date by performing whole-exome sequencing. It is also the first published systematic study to unravel the whole genome of NPC.

Flagship: Asian Prevalent Cancers

Professor Nathalie WONG

Professor Nathalie WONG

Department of Surgery

Professor WONG’s research focuses on elucidating the molecular carcinogenesis of HCC and etiology-associated HCC pathogenesis, namely HBV infection and NASH. Her group has previously studied the cytogenetic aberrations of HCC and defined a number of vital genomic loci.

Flagship: Asian Prevalent Cancers

Professor Jun YU

Professor Jun YU

Department of Medicine and Therapeutics, Institute of Digestive Disease

Professor YU’s novel research activities include detection of molecular alterations in GI carcinogenesis, and discovery of biomarkers for early detection, prognosis prediction and effective treatment. She has obtained 15 research-related prizes/ awards over the years.

Flagship: Asian Prevalent Cancers

Cutting-edge Research

Professor Hui Yao LAN

Professor Hui Yao LAN

Department of Medicine and Therapeutics

Professor LAN devoted his academic efforts to the battle against scarring in the body’s vital organs. He has identified the main pathway that leads to scarring, as well as the molecules that bind with receptors, then proceed down the pathway to the gene and cause or inhibit fibrosis. His discovery could stem the deterioration in patients with diabetes, heart disease or liver damage.

Professor Siew NG

Professor Siew NG

Department of Medicine and Therapeutics

Professor NG’s research interest is to unveil the causes of inflammatory bowel disease (IBD). Her research group has focused on how environmental factors lead to the disease. And their revelations are now being used to developed targeted therapies for IBD.

Professor Ling QIN

Professor Ling QIN

Department of Orthopaedics and Traumatology

Professor QIN has devoted significant efforts to the development of biodegradable metals for clinical applications in orthopaedics. His team has developed a biodegradable magnesium implants, reducing the risk of infection or the need for removal. Further experimental work will be carried in hopes of developing a desirable treatment for major orthopaedic problems.